Literature DB >> 21958946

Acetyl-L-carnitine and α-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy.

Sawsan A Zaitone1, Dina M Abo-Elmatty, Aly A Shaalan.   

Abstract

Although the mechanisms of neurodegeneration in Parkinson's disease are not fully understood, mitochondrial dysfunction, oxidative stress and environmental toxins may be involved. The current research was directed to investigate the protective role of two bioenergetic antioxidants, acetyl-L-carnitine and α-lipoic acid, in rotenone-parkinsonian rats. Ninety six male rats were divided into five groups. Group I is the vehicle-injected group, group II is the disease control group and was injected with six doses of rotenone (1.5 mg/kg/48 h, s.c.). Groups III, IV and V received rotenone in addition to acetyl-L-carnitine (100 mg/kg/day, p.o.), α-lipoic acid (50 mg/kg/day, p.o.) or their combination, respectively. Results showed that rotenone-treated rats exhibited bradykinesia and motor impairment in the open-field and square bridge tests. In addition, ATP level was decreased whereas lipid peroxides and protein carbonyls increased in the striata of rotenone-treated rats as compared to vehicle-treated rats. Treatment with acetyl-L-carnitine or α-lipoic acid improved the motor performance and reduced the level of lipid peroxides in rat brains as compared to rotenone group. Further, ATP production was enhanced along with acetyl-L-carnitine treatments (p≤0.05). Taken together, our study reinforces the view that acetyl-L-carnitine and α-lipoic acid are promising candidates for neuroprotection in Parkinson's disease.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21958946     DOI: 10.1016/j.pbb.2011.09.002

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  29 in total

Review 1.  L-Carnitine and Acetyl-L-carnitine Roles and Neuroprotection in Developing Brain.

Authors:  Gustavo C Ferreira; Mary C McKenna
Journal:  Neurochem Res       Date:  2017-05-16       Impact factor: 3.996

Review 2.  Redox-based therapeutics in neurodegenerative disease.

Authors:  G J McBean; M G López; F K Wallner
Journal:  Br J Pharmacol       Date:  2016-08-25       Impact factor: 8.739

3.  The protective effect of alpha lipoic acid (ALA) on social interaction memory, but not passive avoidance in sleep-deprived rats.

Authors:  Maede Rezaie; Mohammad Nasehi; Salar Vaseghi; Mohammad-Hossein Mohammadi-Mahdiabadi-Hasani; Mohammad-Reza Zarrindast; Mohammad Ali Nasiri Khalili
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-06-24       Impact factor: 3.000

4.  Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease.

Authors:  Ghada A Badawi; Mai A Abd El Fattah; Hala F Zaki; Moushira I El Sayed
Journal:  Inflammopharmacology       Date:  2017-03-04       Impact factor: 4.473

Review 5.  α-Lipoic Acid, an Organosulfur Biomolecule a Novel Therapeutic Agent for Neurodegenerative Disorders: An Mechanistic Perspective.

Authors:  Heena Khan; Thakur Gurjeet Singh; Randhir Singh Dahiya; Mohamed M Abdel-Daim
Journal:  Neurochem Res       Date:  2022-04-21       Impact factor: 3.996

Review 6.  Oxidative damage to macromolecules in human Parkinson disease and the rotenone model.

Authors:  Laurie H Sanders; J Timothy Greenamyre
Journal:  Free Radic Biol Med       Date:  2013-01-15       Impact factor: 7.376

7.  ALCAR Exerts Neuroprotective and Pro-Neurogenic Effects by Inhibition of Glial Activation and Oxidative Stress via Activation of the Wnt/β-Catenin Signaling in Parkinsonian Rats.

Authors:  Sonu Singh; Akanksha Mishra; Shubha Shukla
Journal:  Mol Neurobiol       Date:  2015-07-30       Impact factor: 5.590

8.  Neurorestorative effects of sub-chronic administration of ambroxol in rodent model of Parkinson's disease.

Authors:  Akanksha Mishra; Sairam Krishnamurthy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-10-25       Impact factor: 3.000

9.  Neonatal Rotenone Administration Induces Psychiatric Disorder-Like Behavior and Changes in Mitochondrial Biogenesis and Synaptic Proteins in Adulthood.

Authors:  Amanda Siena; Jéssica Mayumi Camargo Yuzawa; Aline Camargo Ramos; Elisandra Henrique; Mariana Dutra Brito; Mariana Bendlin Calvazara; Tatiana Rosado Rosenstock
Journal:  Mol Neurobiol       Date:  2021-02-19       Impact factor: 5.590

Review 10.  Complementary Therapies for Parkinson's Disease: What's Promoted, Rationale, Potential Risks and Benefits.

Authors:  Marcie L Rabin; Claire Stevens-Haas; Emilyrose Havrilla; Adam Rosenstein; Brittany Toffey; Tanvi Devi; Mary Cathryn Earnhardt; Roger Kurlan
Journal:  Mov Disord Clin Pract       Date:  2015-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.